Telavancin Observational Use Registry (TOUR)

Cumberland Pharmaceuticals

Status: Completed

Conditions: Gram Positive Infection; Complicated Skin and Skin Structure Infections; Ventilator Associated Bacterial Pneumonia; Hospital Acquired Bacterial Pneumonia

Treatments: Drug: Vibativ

Study type: Observational

Funder types: Industry

Identifiers

NCT02288234

0120

Details and patient eligibility

About

The telavancin observational use registry (TOUR) will collect data to support study of the efficacy, safety, and pattern of use of telavancin in hospital-based inpatients and in outpatients being treated in infusion centers who are receiving clinician directed telavancin therapy.

Full description

This is a retrospective medical chart review, multicenter, observational study to examine telavancin efficacy and safety in a real-word setting and to characterize the pattern of use of telavancin in hospital-based inpatients and in outpatient infusion centers. All treatment decisions and clinical assessment will be made at the discretion of the treating physician per usual care and are not mandated by study design or protocol.

Enrollment: 1,063 patients

Sex: All

Volunteers: No Healthy Volunteers

Inclusion criteria

-received at least 1 dose of telavancin since January 1, 2015

Exclusion criteria

• Participation in an interventional research study or clinical trial involving telavancin after January 01, 2015

Trial design

1,063 participants in 1 patient group

Vibativ

Description:

This is an observational study for patients who were already prescribed Vibativ.

Treatment:

Drug: Vibativ